Medical Science and Healthcare

90 Articles in this topic
Technology

Revolutionary Cancer Drug Surv.m-CRA from Kagoshima University Enters Final Trials | First New Bone Tumor Drug in 30 Years

Kagoshima University's oncolytic virus Surv.m-CRA-1 has entered a Phase 3 physician-led trial for primary malignant bone tumors, aiming at full approval. The therapy acts on cancer stem cells that conventional drugs struggle to reach, offering a possible new option for a cancer that has seen no new drug in over 30 years. Inside the mechanism, the Nippon Zoki licensing deal, the 2027 approval target, and what remains unproven.